High thoracic low cervical, long-term intrathecal (IT) infusion of bupivacaine alleviates "refractory" pain in patients with unstable angina pectoris: Report of 2 cases

被引:8
|
作者
Dahm, P [1 ]
Nitescu, P [1 ]
Appelgren, L [1 ]
Curelaru, I [1 ]
机构
[1] Gothenburg Univ, Sahlgrens Hosp, Dept Anaesthesia & Intens Care, S-41345 Gothenburg, Sweden
关键词
unstable angina pectoris; thoracic intrathecal analgesia; intrathecal bupivacaine; pain treatment;
D O I
10.1111/j.1399-6576.1998.tb05363.x
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: There is no reliable treatment for "refractory" pain from unstable angina pectoris (UAP) when epidural infusion of bupivacaine has failed to relieve it. In two such cases we explored the potential of intrathecal (IT) bupivacaine infusion to provide pain relief. Patients and methods: Two female patients, 70 and 67 years. An 18-G nylon catheter was inserted intrathecally through a 17-G Tuohy needle via the T2-T3 interspace and its tip located at the height of C6-C7 vertebrae. The catheter was connected to a portable, programmable electronic pump filled with bupivacaine 5 mg/ml. The infusion started at rates of 0.1-0.2 ml/h, with optional bolus doses of 0.1-0.2 mi 4-2 times/h, respectively, by PCA (Patient-Controlled Analgesia), and then adjusted to give the patients satisfactory (80%-100%) pain relief. Results: Pain relief was obtained with doses of IT-bupivacaine ranging from 17 to 45 (mean=25) mg/d. The pain intensity decreased from VAS (Visual Analogue Score) 9-10 to 0-2 out of 10. The nocturnal sleep improved from 2-4 to 6-7 h. The patients could now ambulate, walking or in a wheel-chair. The IT-treatment lasted 700 and 437 d, of which 540 and 343 d (respectively) were spent at home, and was terminated by: (a) the patient's death due to intracranial bleeding (Ist case); (b) progressive aggravation of the unstable angina that could not be fully countered by increasing the bupivacaine dose above 1.0 mg/h due to occurrence of cerebral transient ischemic attacks, usually not correlated with orthostatic arterial hypotension but apparently facilitated by microembolization of the cerebral arteries (2nd case). Conclusion: IT-bupivacaine infusion may alleviate "refractory" pain in patients with unstable angina pectoris when epidural bupivacaine failed to do so. Its use is apparently Limited by the IT-bupivacaine critical dosage (in these patients=1.0-1.5 mg/h).
引用
收藏
页码:1010 / 1017
页数:8
相关论文
共 25 条
  • [21] Long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 (IL2) activity and efficacy in high-risk relapsed/refractory neuroblastoma patients.
    Lode, Holger N.
    Valteau-Couanet, Dominique
    Garaventa, Alberto
    Gray, Juliet
    Castel, Victoria
    Yaniv, Isaac
    Siebert, Nikolai
    Jensen, Christian
    Endres, Stefanie
    Pill, Lena
    Eger, Christin
    Seidel, Diana
    Juettner, Madlen
    Kietz, Silke
    Ehlert, Karoline
    Janzek, Evelyne
    Loibner, Hans
    Mueller, Ina
    Ladenstein, Ruth L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [22] SINGLE AGENT ACTIVITY OF THE ANTI-GD2 ANTIBODY DINUTUXIMAB BETA LONG-TERM INFUSION IN HIGH-RISK NEUROBLASTOMA PATIENTS WITH RELAPSED AND REFRACTORY DISEASE. A MULTICENTER PHASE II TRIAL
    Lode, Holger
    Ehlert, Karoline
    Huber, Stephanie
    Siebert, Nikolai
    Troschke-Meurer, Sascha
    Zumpe, Maxi
    Loibner, Hans
    Ladenstein, Ruth
    PEDIATRIC BLOOD & CANCER, 2022, 69
  • [23] Randomized use of anti-GD2 antibody dinutuximab beta (DB) long-term infusion with and without subcutaneous interleukin-2 (sclL-2) in high-risk neuroblastoma patients with relapsed and refractory disease: Results from the SIOPEN LTI-trial.
    Lode, Holger N.
    Valteau-Couanet, Dominique
    Gray, Juliet
    Luksch, Roberto
    Wieczorek, Aleksandra
    Castel, Victoria
    Ash, Shifra
    Laureys, Genevieve
    Papadakis, Vassilios
    Owens, Cormac
    Garaventa, Alberto
    Manzitti, Carla
    Siebert, Nikolai
    Troschke-Meurer, Sascha
    Glogova, Evgenia
    Poetschger, Ulrike
    Ladenstein, Ruth Lydia
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [24] Correlation of killer-cell Ig-like receptor (KIR) haplotypes and Fcy-receptor polymorphisms survival of high-risk relapsed/refractory neuroblastoma patients treated by long-term infusion of anti-GD2 antibody chi 4.18/CHO.
    Lode, Holger N.
    Troschke-Meurer, Sascha
    Valteau-Couanet, Dominique
    Garaventa, Alberto
    Gray, Juliet
    Castel, Victoria
    Yaniv, Isaac
    Jensen, Christian
    Eger, Christin
    Juettner, Madlen
    Kietz, Silke
    Ehlert, Karoline
    Janzek, Evelyne
    Loibner, Hans
    Siebert, Nikolai
    Mueller, Ina
    Ladenstein, Ruth
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [25] Low CD4&x207a;/CD25&x207a;/CD127&x207b; regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2
    Troschke-Meurer, Sascha
    Siebert, Nikolai
    Marx, Madlen
    Zumpe, Maxi
    Ehlert, Karoline
    Mutschlechner, Oliver
    Loibner, Hans
    Ladenstein, Ruth
    Lode, Holger N.
    ONCOIMMUNOLOGY, 2019, 8 (12):